According to China International Capital Corporation, on June 18th, Haier Group completed the trading delivery of strategic investment in Shanghai RAAS Blood Products Co., Ltd. China International Capital Corporation acted as Haier Group's financial advisor in the transaction. Haier Group acquired 20% of the shares of Shanghai RAAS held by global medical and health enterprise Grifols for a total price of 12.5 billion yuan through Haiyingkang (Qingdao) Medical Technology Co., Ltd. After completing all transactions, Haiyingkang will have a total voting right of 26.58%. After completing the restructuring in accordance with the agreement, Haier Group will become the actual controller of Shanghai RAAS.
海尔集团完成125亿元战略入股上海莱士
Haier Group has completed a 12.5 billion yuan strategic investment in Shanghai Raas Blood Products.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.